|
Volumn 25, Issue 17, 2015, Pages 3626-3629
|
Ligand efficient tetrahydro-pyrazolopyridines as inhibitors of ERK2 kinase
|
Author keywords
ATP binding cleft; ERK2 kinase; Extraction ratio; Fragment lead; Structure based drug design
|
Indexed keywords
LIGAND;
MITOGEN ACTIVATED PROTEIN KINASE 1;
MITOGEN ACTIVATED PROTEIN KINASE 1 INHIBITOR;
MITOGEN ACTIVATED PROTEIN KINASE INHIBITOR;
PYRAZOLE DERIVATIVE;
PYRIDINE DERIVATIVE;
UNCLASSIFIED DRUG;
ADENOSINE TRIPHOSPHATE;
ASPARTIC ACID;
MAPK1 PROTEIN, HUMAN;
PROTEIN KINASE INHIBITOR;
PYRAZOLOPYRIDINE;
A375 CELL LINE;
ANTAGONIST POTENCY;
ARTICLE;
CELL MEMBRANE PERMEABILITY;
CRYSTAL STRUCTURE;
CRYSTALLIZATION;
DRUG BINDING SITE;
DRUG DESIGN;
DRUG PROTEIN BINDING;
DRUG SCREENING;
ENZYME CONFORMATION;
HYDROGEN BOND;
IC50;
IN VITRO STUDY;
LIPOPHILICITY;
METHYLATION;
PROTEIN INTERACTION;
STRUCTURE ACTIVITY RELATION;
ANIMAL;
ANTAGONISTS AND INHIBITORS;
BINDING SITE;
CHEMICAL STRUCTURE;
CHEMISTRY;
HUMAN;
METABOLISM;
PRECLINICAL STUDY;
PROCEDURES;
PROTEIN CONFORMATION;
RAT;
X RAY CRYSTALLOGRAPHY;
ADENOSINE TRIPHOSPHATE;
ANIMALS;
ASPARTIC ACID;
BINDING SITES;
CRYSTALLOGRAPHY, X-RAY;
DRUG DESIGN;
DRUG EVALUATION, PRECLINICAL;
HUMANS;
LIGANDS;
MITOGEN-ACTIVATED PROTEIN KINASE 1;
MODELS, MOLECULAR;
PROTEIN CONFORMATION;
PROTEIN KINASE INHIBITORS;
PYRAZOLES;
PYRIDINES;
RATS;
STRUCTURE-ACTIVITY RELATIONSHIP;
|
EID: 84938290778
PISSN: 0960894X
EISSN: 14643405
Source Type: Journal
DOI: 10.1016/j.bmcl.2015.06.063 Document Type: Article |
Times cited : (14)
|
References (15)
|